

Form PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

078883/0120

SERIAL NO.

09/533,798 5K

## INFORMATION DISCLOSURE CITATION

MAY 13 2004

(Use several sheets if necessary)

APPLICANT

Miles William CARROLL et al.

FILING DATE

3/24/2000

GROUP ART UNIT

1644 2643

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,118,672	06/92	Schlnazi et al.	514	47	

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A2	99/15684	04/99	WIPO				
	A3	99/15689	04/99	WIPO				
	A4	89/07947	09/89	WIPO				
	A5	92/03568	03/92	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A6	Guschlbauer et al., "Poly-2'-deoxy-2'-fluoro-cytidylic acid: enzymatic synthesis, spectroscopic Characterization and interaction with poly-inosinic acid" 1977 Nucleic Acids Res. 4:1933
	A7	Schibahara et al., "Site-directed cleavage of RNA" 1987 Nucleic Acids Res. 15:4403
	A8	Gershon et al., "The nucleotide sequence around the capripoxvirus thymidine kinase gene reveals a gene Shared specifically with leporipoxvirus" J. Gen. Virol. 70:525, 1989
	A9	Weir et al., "Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous Frameshift mutations" J. Virol. 46:530, 1983
	A10	Esposito et al., "Nucleotide sequence of the thymidine kinase gene region of monkeypox and variola viruses" Virology 135:561, 1984
	A11	Kilpatrick et al., "Cloning and physical mapping of yada monkey tumor virus DNA" Virology 143:399, 1985
	A12	Binns et al., "Comparison of a conserved region in fowlpox virus and vaccinia virus genomes and the translocation of the fowlpox virus thymidine kinase gene" J. Gen. Virol 69:1275, 1988
	A13	Schnitzlein et al., "A rapid method for identifying the thymidine kinase genes of avipoxviruses" J. Virological Method 20:341, 1988
	A14	Fathi et al., "Efficient targeted insertion of an unselected marker into the vaccinia virus genome" Virology 97-105, 1986

EXAMINER

/Marianne Dibrino/

DATE CONSIDERED

05/01/2007

- \* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PT 00449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

078883/0120

SERIAL NO.

09/533,798

MAY 13 2004

INFORMATION DISCLOSURE CITATION

APPLICANT

Miles William CARROLL et al.

FILING DATE

3/24/2000

GROUP ART UNIT

1644 1643

(Use several sheets if necessary)

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

A15

Graham et al., "A new technique for the assay of infectivity of human adenovirus 5 DNA" Virol. 52, 456-467, 1973

A16

Stralbing et al., "Liposomes as carriers for intracellular delivery of nucleic acids" Methods in Enzymology, 101: 512-527 1983

A17

Studier et al., "Use of T7 RNA polymerase to direct expression of cloned genes" Methods in Enzymol. 185: 68-89, 1990

A18

Matthias et al., "Eukaryotic expression vectors for the analysis of mutant proteins" 1989 NAR 17, 6418

A19

Wootton &amp; Federhen, "Statistics of local complexity in amino acid sequences and sequence database" 1993, Computers and Chemistry 17:149-163

A20

Myers et al., "Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein" 1994 J. Biol. Chem 169:9319-9324

A21

Starzynska et al., "Prognostic significance of 5T4 oncofetal antigen expression in colorectal" Br. J. Cancer 1994 May; 69(5):899-902

A22

Starzynska et al., "The expression of 5T4 antigen in colorectal and gastric carcinoma" Br. J. Cancer 1992 Nov; 66(5):867-869

A23

Hobbs et al., "polynucleotides containing 2'-amino-2'-deoxyribose and 2'-azido-2'-deoxyribose" 1973 Biochemistry 12:5138

A24

Starzynska et al., "5T4 oncofetal antigen in gastric carcinoma and its clinical significance" Eur J. Gastroenterol Hepatol 1998 Jun; 10(6):479-484

A25

Carsberg et al., "Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells" 1996, Int J Cancer Sep 27; 68(1):84-92

A26

Yewdell et al., "TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing" 1998 J Immunotherapy 21:127-31

A27

Calvert et al., "Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens" J. of Virol 67:3069-3076, 1993

A28

Carroll et al., "Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen" 1998 J. Natl. Cancer Inst. 90(24):1881-1887

/MD/

A29

"Two bright new faces in gene therapy" Nature Biotechnology 1996 14; 556

EXAMINER

/Marianne Dibrino/

DATE CONSIDERED

05/01/2007

- EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED) MAY 13 2004 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
				APPLICANT Miles William CARROLL et al.	
				FILING DATE 3/24/2000	GROUP ART UNIT 1644 1043
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
/MD/	A30	Ploken et al., "Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes" 1991 Science 253:314-317			
/MD/	A31	Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains" 1994 J. Immunol. 152:163-175			
	A32	Fu et al., "An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope" 1998 J. Virol 72:1469-81			
	A33	Schodel et al., "hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety" 1996 Intervirology 39:104-10			
	A34	Wolff and Trubetskoy, "The cambrian period of nonviral gene delivery" 1998 nature Biotechnology 16:421-423			
	A35	Taylor et al., "Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species" 1995 Vaccine 13:539-549			
	A36	Stannard et al., "Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin" J. Gen. Virol. 1998 79:1637-46			
	A37	Mackett et al., "Vaccinia virus: a selectable eukaryotic cloning and expression vector 1982 PNAS 79: 7415-7419			
	A38	Upton et al, "Identification and nucleotide sequence of the thymidine kinase gene of Shope fibroma virus" J. Virology 60:920, 1986			
	A39	Boyle et al, "Fowlpox virus thymidine kinase: nucleotide sequence and relationships to other thymidine kinases" Virology 156:355-365, 1987			
	A40	Lewis et al, "Human immunodeficiency virus infection of cells arrested in the cell cycle" 1992 EMBO J 11:3053-3058			
	A41	Lewis and Emerman "Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus" 1994 J. Virol. 68:510-516			
	A42	Mackett et al, "General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes" 1984, J. Virol. 49:857-864			
EXAMINER /Marianne Dibrino/			DATE CONSIDERED 05/01/2007		
<p>• EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>					

MAY 13 2004

Sheet 4 of 6

Form PTO-1516  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

078883/0120

SERIAL NO.

09/533,798

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Miles William CARROLL et al.

FILING DATE

3/24/2000

GROUP ART UNIT

1644 1645

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A43

Hruby et al, "Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene"  
PNAS 80:3411-3415, 1983

A44

Lytvyn et al, "Comparison of the thymidine dinase genes from three entomopoxviruses" J. Gen Virol  
73:3235-3240 1992

A45

Smith et al., "Vaccinia virus immune evasion" 1997, Immunol Rev. 159:137-154

A46

Jenkins et al, "Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus"  
AIDS Research and Human Retroviruses 7:991-998, 1991

A47

Taylor et al, "Recombinant fowlpox virus inducing protective immunity in non-avian species" Vaccine 6:497-  
503, 1988

A48

Spheer et al. and Boursnell et al, "Insertion of the fusion gene from newcastle disease virus into a non-  
essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by  
The recombinant" 1990 J. Gen. Virol. 71:621-628

A49

Nakano et al, "Molecular genetics of vaccinia virus: demonstration of marker rescue" Proc. Natl. Acad. Sci.  
USA 79, 1593-1596, 1982

A50

Chakrabarti et al., "Vaccinia virus expression vector: coexpression of  $\beta$ -galactosidase provides visual  
screening of Recombinant virus plaques" Mol. Cell. Biol. 3403-3409, 1985

A51

Wigler et al, "Transformation of mammalian cells with genes from procaryotes and eucaryotes" Cell 777-785,  
1979

A52

Graessmann et al, "Microinjection of tissue culture cells" Meth. Enzymology 101, 482-492, 1983

A53

Franke et al, "Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia  
virus recombinants" Mol Cell Biol 1918-1924, 1985

A54

Altenburger, W., Suter, C.P. and Altenburger J., "Partial deletion of the human host range gene in the  
attenuated vaccinia virus MVA" 1989 Arch. Virol. 105, 15-27

EXAMINER

/Marianne Dibrino/


DATE CONSIDERED

05/01/2007

- EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120		SERIAL NO. 09/533,798	
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)				<b>APPLICANT</b> Miles William CARROLL et al.			
				<b>FILING DATE</b> 3/24/2000		<b>GROUP ART UNIT</b> 1644 1015	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	A55	Neumann et al., "Gene transfer into mouse myoma cell by electroporation in high electric fields" EMBO J. 1, 841-845, 1982					
	A56	<del>Schaffner, "Direct transfer of cloned genes from bacteria to mammalian cells" Proc. Natl. Acad. Sci. USA 77,2163-2167, 1980</del>					
/MD/	A57	Nestle FO et al, "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells" Nat. Med. 1998 Mar;4(3):328-32					
/MD/	A58	Altschul et al, "Issues in searching molecular sequence database" 1994 Nature Genetics 6;119-129.					
/MD/	A59	Carroll & Moss, "Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line", 1997 Virology 238:198-211					
	A60	<del>Kim CJ et al., "Dendritic cell infected with poxviruses encoding Mart-1/melan a sensitive T lymphocytes in vitro" J. Immunother, 1997 Jul;20(4):276-86</del>					
/MD/	A61	Schneider et al., "enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara" 1998 Nat Med 4:397-402					
	A62	<del>Chakrabarti et al., "Compact, synthetic, vaccinia virus early/late promoter for protein expression" 1997 Biotechniques 23:1094-1097</del>					
/MD/	A63	Wyatt et al., "Development of replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model" 1996 Vaccine 14:1451-1458					
	A64	<del>Sutter et al, "A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus", 1994 Vaccine 12:1032-1040</del>					
	A65	Carroll and Moss "E. coli $\beta$ -glucuronidase (GUS) as a marker for recombinant vaccinia viruses" 1995 Biotechniques 19:352-355					
	A66	Hirsch et al., "Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara" 1996 J. Virol 70:3741-3752					
<b>EXAMINER</b> /Marianne Dibrino/				<b>DATE CONSIDERED</b> 05/01/2007			
• <b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120		SERIAL NO. 09/533,798	
<b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)				APPLICANT Miles William CARROLL et al.			
				FILING DATE 3/24/2000		GROUP ART UNIT <b>1644</b> <del>2643</del>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A67	Sutter and Moss, "Nonreplicating vaccinia vector efficiently expresses recombinant genes" 1992 Proc. Natl. Acad Sci USA 89:10847-10851					
	A68	Bronte et al., "Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine" 1997, Proc. Natl Acad Sci USA 94(7):3183-3188					
	A69	Wyatt et al., "Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells" 1995 Virology 210:202-205					
	A70	Carroll et al., "Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model" 1997 Vaccine, 15:387-394					
	A71	Sutter et al, "Non-replication vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase" 1995 FEBS lett. 371:9-12					
/MD/	A72	Overwijk et al, "gp100/pmel 17 is a murine tumor rejection antigen induction of "Self" - reactive, tumoricidal T cells using high-affinity, altered peptide ligand", (1998) J. Exp. Med. 188: 277-286					
	<del>A73</del>	<del>Hole N, and Stern PL, "Isolation and characterization of 5T4, a tumor associated antigen", (1990) Int. J. Cancer 45(1): 179-184</del>					
EXAMINER /Marianne Dibrino/				DATE CONSIDERED 05/01/2007			
• EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120		SERIAL NO. 09/533,798	
 <b>INFORMATION DISCLOSURE CITATION</b>				APPLICANT Miles William CARROLL and Kevin Alan MYERS			
				FILING DATE March 24, 2000		GROUP ART UNIT 1643	
Date Submitted to PTO: September 6, 2000							
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	A1	EP-A-0198328	04/02/86	Europe			
	A2	EP A 0110285	11/20/83	Europe			
<b>OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
<b>EXAMINER</b> /Marianne Dibrino/				<b>DATE CONSIDERED</b> 05/01/2007			
* <b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/774,176
				Filing Date	February 6, 2004
				First Named Inventor	Carroll, Miles W.
				Art Unit	1644
				Examiner Name	Marianne NMN Dibrino
Sheet	1	of	1	Attorney Docket Number	021911-000510US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/MD/	AA	US-5,889,053	02/09/1999	Stern, et al.	
	AB	US-			
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AS							<input type="checkbox"/>
	AT							<input type="checkbox"/>
	AU							<input type="checkbox"/>
	AV							<input type="checkbox"/>
	AW							<input type="checkbox"/>

Examiner Signature	/Marianne Dibrino/	Date Considered	04/30/2007
-----------------------	--------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/774,176		
		Filing Date	February 6, 2004		
		First Named Inventor	Carroll, Miles W.		
		Art Unit	1644		
		Examiner Name	Marianne NMN Dibrino		
Sheet	1	of	3	Attorney Docket Number	021911-000510US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
/MD/	AA	US-4,558,035	12/10/1985	Johnson	
	AB	<del>US-6,000,000</del>	<del>02/00/1999</del>	<del>Stem, et al</del>	
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AN							<input type="checkbox"/>
	AO							<input type="checkbox"/>
	AP							<input type="checkbox"/>
	AQ							<input type="checkbox"/>
	AR							<input type="checkbox"/>

Examiner Signature	/Marianne Dibrino/	Date Considered	04/30/2007
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

61000823 v1

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/774,176
				Filing Date	February 6, 2004
				First Named Inventor	Carroll, Miles W.
				Art Unit	1644
				Examiner Name	Marianne NMN Dibrino
Sheet	2	of	3	Attorney Docket Number	021911-000510US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
/MD/	AS	COULIE P. "Human Tumor Antigens Recognized by Cytolytic T Lymphocytes", Chapter 5, pages 95-125, <i>Tumor Immunology</i> , Eds. Dagleish & Browning, Cambridge University Press 1996	<input type="checkbox"/>	
	AT	ROSENKRANTZ, K., et al. "Generation and regulation of aut cytotoxicity in mixed lymphocyte cultures: Evidence for active suppression of aut cytotoxic cells", <i>PNAS</i> (1985) 82:4508-4512	<input type="checkbox"/>	
	AU	STAVELY-O'CARROLL, et al. "Induction of antigen-specific T cell energy: An early event in the course of tumor progression", <i>PNAS</i> (1998) 95:1178-1183	<input type="checkbox"/>	
	AV	MANSON, L, et al. "Short Analytical Review - Anti-tumor Immune Responses of the Tumor Bearing Host: The Case for Antibody-Mediated Immunologic Enhancement", <i>Clinical Immunology &amp; Immunopathology</i> (1994) 72(1):1-8	<input type="checkbox"/>	
	AW	GANSS, R., et al. "Tumor Microenvironment Can Restrict the Effectiveness of Activated Antitumor Lymphocytes", <i>Cancer Research</i> (1998) 58:4673-4681	<input type="checkbox"/>	
	AX	BERD, D. "Cancer Vaccines: Reborn or Just Recycled?", <i>Seminars in Oncology</i> (1998) 25(6):605-610	<input type="checkbox"/>	
	AY	HERSEY, P., et al. "Impediments to Successful Immunotherapy", <i>Pharmacol. Ther.</i> (1999) 81(2):111-119	<input type="checkbox"/>	
	AZ	TAKAHASHI, K., et al. "Escape Mechanisms of Melanoma From Immune System By Soluble Melanoma Antigen", <i>The Journal of Immunology</i> (1988) 140(9):3244-3248	<input type="checkbox"/>	
	BA	JANEWAY & TRAVERS, <i>Immunobiology: The Immune System in Health and Disease</i> , Third edition, Current Biology Ltd./Garland Publishing Inc. (1997), <b>P. 12:2</b>	<input type="checkbox"/>	
	BB	AMATO, R., et al. "Phase II Trial to Assess the Activity of MVA 5T4 (Trovax®) alone versus MVA 5T4 plus Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in Patients (pts) with Progressive Hormone Refractory Prostate Cancer (HRPC), Abstract, 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", 7-10 November 2006, Prague, Czech Republic	<input type="checkbox"/>	
/MD/	BC	AMATO, R., et al. "Activity of MVA 5T4 alone or in Combination with either Interleukin-2 (IL-2), Interferon-α (IFN), or Sunitinib in Patients (Pts) with Metastatic Renal Cell Cancer (MRCC), Abstract, 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", 7-10 November 2006, Prague, Czech Republic	<input type="checkbox"/>	

Examiner Signature	/Marianne Dibrino/	Date Considered	04/30/2007
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/774,176
				Filing Date	February 6, 2004
				First Named Inventor	Carroll, Miles W.
				Art Unit	1644
				Examiner Name	Marianne NMN Dibrino
Sheet	3	of	3	Attorney Docket Number	021911-000510US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
/MD/	BD	SYKULEV, Y., et al. "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response", <i>Immunity</i> (1996) 4:565-571	<input type="checkbox"/>	
/MD/	BE	STERN, Peter, et al. "Characterization of the Human Trophoblast-Leukocyte Antigenic Molecules Defined by a Monoclonal Antibody", <i>The Journal of Immunology</i> (1986) 137(5):1604-1609	<input type="checkbox"/>	
	BF	JOHNSON, P.M., et al. "Human Trophoblast-Specific Surface Antigens Identified Using Monoclonal Antibodies", <i>American Journal of Reproductive Immunology</i> (1981) 1:246-264	<input type="checkbox"/>	
/MD/	BG	RETTIG, Wolfgang J., et al. "Cell Surface Antigens of Human Trophoblast and Choriocarcinoma Defined by Monoclonal Antibodies", <i>Int. J. Cancer</i> (1985) 35:469-475	<input type="checkbox"/>	
/MD/	BH	HOLE, M., et al. "Trophoblast-Specific Glycoprotein Defined by Monoclonal Antibody 5T4", <i>British Society for Immunology &amp; British Transplantation Society 1986 Joint Annual Meeting</i> , November 12-14, 1986, abstract 66.	<input type="checkbox"/>	
/MD/	BI	STERN, P.L. et al. "Molecular Characterisation of Human Terato-Carcinoma-Trophoblast Cell Surface Antigens", <i>J. Repro. Immun., Supp.</i> 6 (June 1986)	<input type="checkbox"/>	
/MD/	BJ	ANDERSON, Deborah J., et al. "Monoclonal antibodies to human trophoblast and sperm antigens: Report of two WHO sponsored workshops, June 30, 1986 - Toronto, Canada <i>J. Repro. Immun.</i> (1987) 10:231-257	<input type="checkbox"/>	
/MD/	BK	CHO, S.-W., et al. "Characterization of three monoclonal antibodies to membrane co-factor protein (MCP) of the complement system and quantification of MCP by radioassay", <i>Clin. Exp. Immunol.</i> (1991) 83:257-261	<input type="checkbox"/>	
/MD/	BL	PURCELL, D.F.J., et al. "The human cell-surface glycoproteins HuLy-m5, membrane co-factor protein (MCP) of the complement system, and trophoblast leucocyte-common (TLX) antigen, are CD46", <i>Immunology</i> (1990) 70:155-161	<input type="checkbox"/>	
	BM		<input type="checkbox"/>	

Examiner Signature	/Marianne Dibrino/	Date Considered	04/30/2007
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.